A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
-
REGULATORY Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
-
BUSINESS CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
-
BUSINESS Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
March 16, 2023
-
BUSINESS Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
-
BUSINESS Eisai’s Leqembi Wins Coverage from US Veteran’s Body
March 15, 2023
-
BUSINESS Bayer Setting Out to Cut Up to 480 Jobs as Xarelto Patent Cliff Looms: Employee
March 14, 2023
-
BUSINESS AstraZeneca Looks to 1st IO/ADC Launch as Leader in the Race: Oncology Head
March 13, 2023
-
ORGANIZATION PhRMA Unveils Proposal for FY2024 Reform, Says This Year Is “Turning Point” to Improve Access
March 10, 2023
-
REGULATORY Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
-
REGULATORY Expert Narukawa Backs JPMA Pitch on Value-Based Pricing, but Disputes Blanket Price Maintenance for Patented Meds
March 8, 2023
-
BUSINESS Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
-
BUSINESS Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
-
BUSINESS 2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023
-
REGULATORY MHLW Unveils New List Prices for FY2023 Revision, Ad-Hoc PMP Raise for 143 Products
March 3, 2023
-
BUSINESS Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
-
BUSINESS Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
-
BUSINESS Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
-
REGULATORY Japan Panel Backs Approval of 1st Nasal Flu Vaccine
February 28, 2023
-
REGULATORY Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…